TERN - NASDAQ
Terns Pharmaceuticals, Inc.
$52.95
+0.0000%Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
At a Glance
Live SnapshotTerns Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
Terns Pharmaceuticals, Inc. Income Statement
TERN • NASDAQ
| Terns Pharmaceuticals, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
0.0 | 0.0 | 0.0 | 0.0 | 1M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (195K) | (65K) | |
0.0 | 0.0 | 0.0 | 0.0 | 1M | 0.0 | -195K | -65K | |
OPERATING INCOME | ||||||||
(110.1M) | (101.9M) | (102.6M) | (62M) | (50.9M) | (37M) | (70.2M) | (18.5M) | |
(32.2M) | (31.8M) | (39.1M) | (22.4M) | (19.5M) | (9M) | (8.7M) | (3.9M) | |
(77.9M) | (70.1M) | (63.5M) | (39.6M) | (31.3M) | (28M) | (61.5M) | (14.6M) | |
-110.1M | -101.9M | -102.6M | -62M | -49.9M | -37M | -70.2M | -18.5M | |
PRE-TAX INCOME | ||||||||
14.6M | 13.3M | 12.9M | 2.1M | 170K | 55K | 1.2M | 0.0 | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (154K) | (38K) | |
14.5M | 13.3M | 12.6M | 2M | 210K | 8M | 1.4M | 370K | |
-95.6M | -88.6M | -90M | -60M | -49.7M | -29.1M | -68.8M | -18.1M | |
NET INCOME | ||||||||
(581K) | (260K) | (239K) | (358K) | (508K) | (813K) | -20K | -67K | |
-96.2M | -88.9M | -90.2M | -60.3M | -50.2M | -29.4M | -68.8M | -17.7M |
SEC Filings
TERN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 05, 2026 | May 05, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 27, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 22, 2026 | January 16, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 11, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 08, 2025 | December 08, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 10, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your TERN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.